Akcea Therapeutics, Inc. (AKCA) Reaches $22.85 After 3.00% Up Move; 6 Bullish Analysts Covering MACOM Technology Solutions Holdings, Inc. (MTSI)

June 12, 2018 - By Hazel Jackson

MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI) Logo

Among 13 analysts covering M/A-Com Technology Solutions Holdings (NASDAQ:MTSI), 6 have Buy rating, 1 Sell and 6 Hold. Therefore 46% are positive. M/A-Com Technology Solutions Holdings had 52 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Overweight” rating by Barclays Capital given on Wednesday, November 15. The stock of MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI) has “Buy” rating given on Tuesday, September 5 by Needham. The rating was maintained by Needham on Tuesday, August 18 with “Buy”. On Wednesday, November 15 the stock rating was maintained by Stifel Nicolaus with “Hold”. The firm has “Hold” rating given on Friday, April 27 by Stifel Nicolaus. The company was maintained on Wednesday, November 15 by JP Morgan. Needham maintained MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI) rating on Wednesday, May 2. Needham has “Buy” rating and $3400 target. Jefferies maintained the shares of MTSI in report on Wednesday, October 18 with “Buy” rating. Bank of America maintained it with “Underperform” rating and $25 target in Wednesday, February 7 report. Stifel Nicolaus maintained it with “Hold” rating and $30.0 target in Tuesday, February 6 report. See MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI) latest ratings:

02/05/2018 Broker: Craig Hallum Rating: Buy New Target: $31.0000 Maintain
02/05/2018 Broker: Needham Rating: Buy New Target: $34.0000 Maintain
27/04/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Old Target: $25 New Target: $18 Maintain
04/04/2018 Broker: Northland Capital Rating: Outperform New Target: $25 Initiates Coverage On
27/02/2018 Broker: PiperJaffray Rating: Neutral New Target: $22 Initiates Coverage On
07/02/2018 Broker: Craig Hallum Rating: Buy New Target: $36.0 Maintain
07/02/2018 Broker: Barclays Capital Rating: Hold New Target: $26.0 Downgrade
07/02/2018 Broker: J.P. Morgan Rating: Hold New Target: $26.0 Downgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $34.0
07/02/2018 Broker: Jefferies Rating: Buy New Target: $43.0 Maintain

The stock of Akcea Therapeutics, Inc. (NASDAQ:AKCA) is a huge mover today! The stock increased 3.72% or $0.82 during the last trading session, reaching $22.85. About 124,753 shares traded. Akcea Therapeutics, Inc. (NASDAQ:AKCA) has 0.00% since June 12, 2017 and is . It has underperformed by 12.57% the S&P500. Some Historical AKCA News: ; 17/04/2018 – Akcea and Ionis Plan to Commence Clinical Studies for AKCEA-TTR-L in 2018; 17/04/2018 – Akcea, Ionis: Regulatory Approval of Inotersen and AKCEA-TTR-L Will Trigger Milestones to Ionis of $50M and $40M, Respectively; 08/05/2018 – STAT Plus: Biotech updates: Amicus, Aveo Oncology, Akcea Therapeutics and Ionis Pharma; 17/04/2018 – Sarah Boyce Joins Akcea Therapeutics as President and Member of the Board of Directors; 11/05/2018 – AKCEA THERAPEUTICS INC AKCA.O : WELLS FARGO RAISES TO OUTPERFORM FROM MARKET PERFORM; 21/03/2018 – MHRA Grants UK Patients Early Access to Akcea Therapeutics’ Volanesorsen for Familial Chylomicronaemia Syndrome (FCS); 17/04/2018 – Ionis’ Ownership in Akcea Increased by 7% From 68% to 75%; 17/04/2018 – Akcea and Ionis Complete Licensing Transaction to Commercialize lnotersen for hATTR; 12/03/2018 – Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo; 26/03/2018 – Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on AmyloidosisThe move comes after 5 months positive chart setup for the $1.96B company. It was reported on Jun, 12 by Barchart.com. We have $23.54 PT which if reached, will make NASDAQ:AKCA worth $58.68M more.

More notable recent Akcea Therapeutics, Inc. (NASDAQ:AKCA) news were published by: Streetinsider.com which released: “Akcea Therapeutics (AKCA), Ambry Genetics to Launch hATTR Compass Genetic Testing Program” on June 12, 2018, also Globenewswire.com with their article: “Akcea and Ionis Receive Positive EU CHMP Opinion for TEGSEDI” published on June 01, 2018, Seekingalpha.com published: “Eidos Therapeutics files for initial public offering” on May 25, 2018. More interesting news about Akcea Therapeutics, Inc. (NASDAQ:AKCA) were released by: Seekingalpha.com and their article: “Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells” published on June 08, 2018 as well as Nasdaq.com‘s news article titled: “Akcea Therapeutics Appoints Industry Leader Dr. Richard Moscicki to Board of Directors” with publication date: June 05, 2018.

Akcea Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The company has market cap of $1.96 billion. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy. It currently has negative earnings. The firm also develops AKCEA-APO-LRx, which has completed Phase 2b clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase 1/2 clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase 1/2 study for the treatment of cardiovascular disease driven by high triglycerides.

Analysts await Akcea Therapeutics, Inc. (NASDAQ:AKCA) to report earnings on August, 14. They expect $-0.58 earnings per share, down 114.81% or $0.31 from last year’s $-0.27 per share. After $-0.44 actual earnings per share reported by Akcea Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 31.82% negative EPS growth.

Among 3 analysts covering Akcea Therapeutics Inc (NASDAQ:AKCA), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Akcea Therapeutics Inc had 5 analyst reports since August 8, 2017 according to SRatingsIntel. On Tuesday, August 8 the stock rating was initiated by BMO Capital Markets with “Buy”. The company was initiated on Tuesday, August 8 by Stifel Nicolaus. On Tuesday, November 7 the stock rating was maintained by Stifel Nicolaus with “Buy”. The company was maintained on Tuesday, October 31 by Stifel Nicolaus.

MACOM Technology Solutions Holdings, Inc., together with its subsidiaries, creates and makes analog RF, microwave, millimeter wave, and photonic semiconductor solutions in the United States, the Asia Pacific, and internationally. The company has market cap of $1.67 billion. The firm offers a portfolio of standard and custom devices, which include integrated circuits, multi-chip modules, power pallets and transistors, diodes, amplifiers, switches and switch limiters, passive and active components, and complete subsystems for approximately 40 product lines. It currently has negative earnings. The Company’s semiconductor products are electronic components that are incorporated in electronic systems, such as point-to-point wireless backhaul radios, high density networks, active antenna arrays, radars, magnetic resonance imaging systems, and unmanned aerial vehicles.

The stock increased 1.58% or $0.4 during the last trading session, reaching $25.77. About 434,603 shares traded. MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI) has declined 62.38% since June 12, 2017 and is downtrending. It has underperformed by 74.95% the S&P500. Some Historical MTSI News: ; 03/05/2018 – MACOM to Attend the Goldman Sachs Leveraged Finance Conference on May 10; 23/05/2018 – MACOM to Showcase Industry Leading RF and Microwave Portfolio at IMS 2018; 22/04/2018 – DJ MACOM Technology Solutions Holdings, Inst Holders, 1Q 2018 (MTSI); 29/03/2018 – MACOM’s Innovative 12G-SDI Product and Technology Solutions to Enhance the Future of UHD; 01/05/2018 – MACOM 2Q REV. $150.4M, EST. $145.5M; 09/05/2018 – MACOM TECHNOLOGY SOLUTIONS HOLDINGS – AMENDMENT EXTENDED MATURITY OF REMAINING $30 MLN OF COMMITMENTS UNDER FACILITY UNTIL NOVEMBER 2021; 12/03/2018 – MACOM Expands 5G Optical Connectivity Portfolio with 28Gbps TIAs for CPRI and Ethernet Applications; 12/03/2018 – MACOM to Drive Cloud Data Centers and 5G Optical Connectivity with L-PIC™-Enabled Solutions for CWDM4; 09/03/2018 – S&P REVISES MACOM TECHNOLOGY SOLUTIONS HOLDINGS, INC. TO RATING ‘B’ FROM ‘B+’; OUTLOOK ‘STABLE’; 02/05/2018 – MACOM Announces Extension of Revolving Credit Facility

Investors sentiment increased to 1.35 in 2018 Q1. Its up 0.41, from 0.94 in 2017Q4. It improved, as 29 investors sold MACOM Technology Solutions Holdings, Inc. shares while 31 reduced holdings. 28 funds opened positions while 53 raised stakes. 59.38 million shares or 2.96% more from 57.67 million shares in 2017Q4 were reported. Natixis Advsr Ltd Partnership stated it has 0.01% of its portfolio in MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI). 36,446 were accumulated by Quantbot Technologies Limited Partnership. Icon Advisers Inc invested 0.01% of its portfolio in MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI). Ftb Advsrs holds 0% of its portfolio in MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI) for 419 shares. Guggenheim Capital holds 41,568 shares. Cubist Systematic Strategies Lc stated it has 0.04% in MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI). Pennsylvania-based Pnc Financial Service Gru has invested 0% in MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI). 1.80 million are held by Neuberger Berman Grp Ltd Liability. Ameritas Partners reported 3,561 shares. Parametric Portfolio Assoc Llc invested in 0% or 226,048 shares. Colrain Capital Ltd owns 124,275 shares. Granite Invest Prtn Llc holds 295,218 shares or 0.33% of its portfolio. Geode Management Ltd accumulated 392,868 shares or 0% of the stock. Crow Point Prtnrs Limited Liability stated it has 0% in MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI). 2.50M are owned by Blackrock Inc.

MACOM Technology Solutions Holdings, Inc. (NASDAQ:MTSI) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>